Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomudex plus Radiotherapy in Inoperable or Recurrent Rectal Cancer
NCT00590278Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed in rectal cancer, sponsored by AstraZeneca. Primary endpoints: Response Rate and Resectability Rate. Started Aug 2002; status: completed.
02
Drugs
raltitrexed
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00590278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590278.